Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other
programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (t
programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount
of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment
duration; availability
of funding for state AIDS Drug Assistance
Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (t
Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction
of generic versions
of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect
of lowering prices or reducing the number
of insured patients; the possibility
of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels
of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits
of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or
at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages
of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory
programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (t
programs; safety and efficacy data from clinical studies may not warrant further development
of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase
program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate
of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
The Central banker announced an adjustment in the «size, composition and
duration»
of the bond - buying
program, with a decision to be taken
at the next meeting on 6 December.
RIAs are eligible to participate in the
Program if they represent to Fidelity Investments that they meet the following criteria: (1) RIA is an investment adviser registered and in good standing with the U.S. Securities and Exchange Commission and / or any applicable state securities regulatory authorities or is exempt from such registration; (2) RIA's representatives who provide services to referred clients are appropriately registered / licensed as «Investment Advisers Representatives» in required jurisdictions; (3) RIA charges fee - based, asset - based, or flat - rate investment advisory service fees (which may include hourly fees); (4) RIA will maintain a minimum
of $ 350,000,000 in total regulatory assets under management, as reported in response to Item 5 in Part 1A
of the RIA's Form ADV, throughout the
duration of RIA's participation in the
Program; (5) RIA and all associated persons
of the RIA who manage client assets or who supervise such associated persons shall
at all times be covered through both Errors and Omissions Liability Insurance and Fidelity Bond Coverage; and (6) RIA maintains a minimum
of two principals or officers as well as a minimum
of five employees.
At the beginning
of a strenuous exercise
program or after traveling to a warmer climate, the intensity and
duration of exercise should be limited initially and then gradually increased during a period
of 10 to 14 days to accomplish acclimatization to the heat.
«With improved energy density and inherent fire safety, flow batteries could provide long -
duration energy storage for the tight confines
of urban settings, where space is
at a premium,» said Imre Gyuk, energy storage
program manager
at the Department
of Energy's Office
of Electricity Delivery and Energy Reliability, which funded this research.
«By using ultrafast lasers, which are very intense but very short in
duration (
of the order
of a billion trillion flashes per second), we have realized a world record in optical quality, where all the obtained shaped particles behave like nano - sized clones,» explains Andrés Guerrero Martínez, researcher
of the Ramón y Cajal
Program at the Faculty
of Chemical Sciences
of the UCM.
«Our stewardship
program goal is to empower and engage our providers to choose and prescribe the right antibiotic
at the right dose and for the right
duration,» says Tejal Gandhi, M.D., associate professor
of infectious diseases and physician co-lead
of Michigan Medicine's Infectious Diseases and Antimicrobial Stewardship
program.
These
programs provide opportunities for visiting professionals from industry or universities to participate in established research studies
at Ames Laboratory, usually for periods
of six months to one year in
duration.
This is just a matter
of proper workout
programming, and the factors
at play are the
duration and intensity
of both your high - and low - intensity intervals and
of the workouts as a whole.
This ensures you'll perform your best — functioning
at or near 100 % for the
duration of your
program.
Students who are currently enrolled in a CNME - accredited naturopathic medical
program are invited to join the GastroANP
at the rate
of $ 40 annually for the
duration of their schooling.
The field experience must begin within the first semester
of enrollment in the ECE
program and continue for the
duration of the ECE
program at CU Denver.
To qualify, you or your spouse or common - law partner must be enrolled or committed to enrol as a full - time student in a qualifying education
program of at least three months»
duration at a designated educational institution.
You can sign up for the
program either when you start the policy or
at any point in the
duration of your policy.
At the time a servicer provides the written notice pursuant to § 1024.41 (c)(2)(iii), if the servicer lacks information necessary to determine the amount of a specific payment due during the program or plan (for example, because the borrower's interest rate will change to an unknown rate based on an index or because an escrow account computation year as defined in § 1024.17 (b) will end and the borrower's escrow payment might change), the servicer complies with the requirement to disclose the specific payment terms and duration of a short - term payment forbearance program or short - term repayment plan if the disclosures are based on the best information reasonably available to the servicer at the time the notice is provided and the written notice identifies which payment amounts may change, states that such payment amounts are estimates, and states the general reason that such payment amounts might chang
At the time a servicer provides the written notice pursuant to § 1024.41 (c)(2)(iii), if the servicer lacks information necessary to determine the amount
of a specific payment due during the
program or plan (for example, because the borrower's interest rate will change to an unknown rate based on an index or because an escrow account computation year as defined in § 1024.17 (b) will end and the borrower's escrow payment might change), the servicer complies with the requirement to disclose the specific payment terms and
duration of a short - term payment forbearance
program or short - term repayment plan if the disclosures are based on the best information reasonably available to the servicer
at the time the notice is provided and the written notice identifies which payment amounts may change, states that such payment amounts are estimates, and states the general reason that such payment amounts might chang
at the time the notice is provided and the written notice identifies which payment amounts may change, states that such payment amounts are estimates, and states the general reason that such payment amounts might change.
SoFi's average lifetime savings methodology for its Employer Contribution
Program assumes: 1) data entered during enrollment in the contribution program is accurate; 2) enrollees» interest rates do not change over time (PROJECTIONS FOR VARIABLE RATES ARE STATIC AT THE TIME OF REFINANCING AND DO NOT REFLECT ACTUAL MOVEMENT OF RATES IN THE FUTURE); 3) enrollees make all payments on time 4); enrollees make their minimum monthly payment for the full duration of their loan; 5) employer contribution is applied for the duration of the enrollee's loan; and 6) enrollee remains employed by the company for the duration of thei
Program assumes: 1) data entered during enrollment in the contribution
program is accurate; 2) enrollees» interest rates do not change over time (PROJECTIONS FOR VARIABLE RATES ARE STATIC AT THE TIME OF REFINANCING AND DO NOT REFLECT ACTUAL MOVEMENT OF RATES IN THE FUTURE); 3) enrollees make all payments on time 4); enrollees make their minimum monthly payment for the full duration of their loan; 5) employer contribution is applied for the duration of the enrollee's loan; and 6) enrollee remains employed by the company for the duration of thei
program is accurate; 2) enrollees» interest rates do not change over time (PROJECTIONS FOR VARIABLE RATES ARE STATIC
AT THE TIME
OF REFINANCING AND DO NOT REFLECT ACTUAL MOVEMENT OF RATES IN THE FUTURE); 3) enrollees make all payments on time 4); enrollees make their minimum monthly payment for the full duration of their loan; 5) employer contribution is applied for the duration of the enrollee's loan; and 6) enrollee remains employed by the company for the duration of their loa
OF REFINANCING AND DO NOT REFLECT ACTUAL MOVEMENT
OF RATES IN THE FUTURE); 3) enrollees make all payments on time 4); enrollees make their minimum monthly payment for the full duration of their loan; 5) employer contribution is applied for the duration of the enrollee's loan; and 6) enrollee remains employed by the company for the duration of their loa
OF RATES IN THE FUTURE); 3) enrollees make all payments on time 4); enrollees make their minimum monthly payment for the full
duration of their loan; 5) employer contribution is applied for the duration of the enrollee's loan; and 6) enrollee remains employed by the company for the duration of their loa
of their loan; 5) employer contribution is applied for the
duration of the enrollee's loan; and 6) enrollee remains employed by the company for the duration of their loa
of the enrollee's loan; and 6) enrollee remains employed by the company for the
duration of their loa
of their loan.
Credit card companies DO have hardship
programs (although none
of my 13 creditors offered such a
program, nor were they known to me
at the time), but they typically have a
duration of one year, which typically is not enough time for a person heavily in debt to pay off the money they owe.
Starmark Academy provides boarding, food, and training to these dogs
at no charge to the rescue groups for the
duration of the training
program.
a) Institutional — Open to those schools, colleges, universities, and organizations which are accredited by national or regional educational accrediting bodies and which offer professional veterinary technician educational
programs at the post-secondary level which are
of two academic years or equivalent in
duration or greater.
Members
of the Global Entry
program may use Global Entry kiosks
at any participating airport for a
duration of five years.
*
Durations: Half day, Full Day and Extended (overnight) * Departures: Daily * Language speaking guides Tour
Programs Half Day — 4 hrs City Sights Fashionista Style Tour Aboriginal Culture & Heritage Healesville Sanctuary Full Day — 7/8 hrs (flexible) Yarra Valley Dandenong Ranges / Yarra Valley / Healesville Sanctuary - combinations Mornington Peninsula Sovereign Hill and Ballarat Mt Macedon and the Spa Country Penguins and Koalas
at Phillip Island Extended Great Ocean Road — 12 hours Cattlemen
of «The High Country» — 12 hours (Fly / Drive combination saves 4 hours) Great Ocean Road / Grampians — two / three days Melbourne — Adelaide - Kangaroo Island Melbourne - Mildura — Mungo National Park 2 days / 3 nights Snow Skiing - Mt Buller Special Interest: Collectibles, Object d' Art, Art Jewellery, Antiquities, Indigenous artifacts — by appointment.
The computer is
programmed with a set
of rules to select pitch, loudness, and
duration, and to repeat the notes
at specific intervals.
In addition to the events held
at the space, the Videorover Archive from Seasons 3 through 8 were on display for the
duration of the exhibition, re-activating the works which are the foundation
of this
program.
If you're currently enrolled in a class
at VisArts, you can take advantage
of our open studio
program, free
of charge, for the
duration of your class.
For this multi-faceted performance, Hundley will «set up shop»
at the gallery, returning to his archive
of stencils to reproduce favorite shirts, which will then be displayed for sale, as well as
programming a block
of radio to stream on Know Wave (know-wave.com) for the
duration of gallery hours on Saturday.
You can sign up for the
program either when you start the policy or
at any point in the
duration of your policy.
Additionally, for a third or subsequent violation
of requirements for installation
of an ignition interlock device, a person must complete treatment as determined by a licensed treatment agency following a referral by a DUI
program and have the
duration of the ignition interlock device requirement extended by
at least 1 month up to the time period required to complete treatment.
Our
program automatically saves your progress as you go, so you are able to stop
at any time during the
duration of taking traffic school.
Scoring
programs for the CAPA and YAPA, written in SAS, 41 combined information about the date
of onset,
duration, and intensity
of each symptom to create diagnoses according to the DSM - IV.29 With the exception
of attention - deficit / hyperactivity disorder (ADHD), for which only parental reports were counted, a symptom was counted as present if it was reported by either the parent or the child until age 16 years or by the young adult
at ages 19 and 21 years, as is standard clinical practice.
The practicum should include
at least 8 hours per month up to full - time employment, for the
duration of the 22 month
program, and should generate cases for case studies and peer - to - peer mentorship.
ABFT, however, is a 12 - week
program; thus, it is only possible to test for differences in the outcomes for the waitlist control group with those
of the ABFT group
at six weeks, one - half
of the full
duration of ABFT.
This finding is in line with findings
of a meta - analysis on effective ingredients
of prevention
programs for youth
at risk for juvenile delinquency, which also showed that preventive interventions
of shorter
duration were more effective than preventive interventions
of longer
duration (De Vries et al. 2015).